Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicentre clinical study in asthma

Thorax

Volumn 52, Issue 6, 1997, Pages 523-527

  Barnes, N C ^a   Pujet, J C ^b  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b Ctr de Diagn et de Readaptation R   (France)

Author keywords

Asthma; Leukotriene receptor antagonist; ONO 1078; Pranlukast; SB 205312

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; PRANLUKAST;

ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030872408     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.6.523     Document Type: Article

References (15)

1. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Nat Acad Sci USA 1979;76:4275-9.
2. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204, 219 on allergen-induced bronchoconstriction and airway hyperactivity in atopic subjects. Lancet 1991;337:690-4.
3. 4 receptor antagonist, MK-571. Ann NY Acad Sci 1991;629:436.
4. 4 receptor antagonist. N Engl J Med 1990;323:1736-9.
5. Israel E, Dermarkian R, Rosenberg M, Sperling R, Taylor G, Rubin P, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323:1740-4.
6. 4 receptor antagonist improves pulmonary function in patients with mild chronic asthma. Am Rev Respir Dis 1989;140:1336-9.
7. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993;119:1059-66.
8. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
9. 4 and antigen in vitro. Am Rev Respir Dis 1992;146:923-9.
10. Taniguchi Y, Tamura G, Honma M, Aizawa T, Maruyama N, Shirato K, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993;92:507-12.
11. Nakagawa N, Obata T, Kobayashi T, Okada Y, Nambu F, Terawaki T, et al. In vivo pharmacologie profile of ONO-1078: a potent, selective and orally active peptide leukotriene (LT) antagonist. Japan J Pharmacol 1992;60:217-25.
12. 4. Eur Respir J 1995;8(Suppl 19):288s.
13. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993;87:133-8.
14. Taki P, Suzuki R, Tori K, Mutsamoto S, Taniguchi H, Tukagi K. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate. Drug Res 1994;44:330-3.
15. 4) challenge in normal volunteers. Thorax 1997;52:524-7.